Overslaan en naar de inhoud gaan

Hoe kunnen we u helpen?

Deze pagina is niet beschikbaar in deze taal. Deze pagina is beschikbaar in de volgende talen:

  • Engels

Corporate highlights include advising:

  • Acerta Pharma B.V. on its 55% acquisition by AstraZeneca for USD 4 billion, with options to require the remainder of shares for another USD 3 billion, which is the biggest Dutch pharma deal ever.
  • Amylon on its seed investment.
  • Arvelle Therapeutics in its USD 180 million (€159.1m) Series A round series A financing led by LSP.
  • AstraZeneca on the Dutch aspects of the sale of its business Astra Tech to Dentsply.
  • Bain Capital in its acquisition of DSM Sinochem.
  • BC Partners' acquisition of Synthon.
  • Beaver Visitec/TPG on its acquisition of Vitreq, a Netherlands based next-generation ophthalmic technology company.
  • Calypso Biotech; assisting Gilde Healthcare, M-Ventures, INKEF Capital and JJDC on its series A investment in Calypso Biotech.
  • Coopération Pharmaceutique Française S.A.S. (Cooper), one of the largest independent OTC players in France, with the acquisition of the Vemedia Group from funds managed and advised by IK Investment Partners.
  • Dezima Pharma, a Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia, and its shareholders in its up to 1.5 billion acquisition by Amgen.
  • Elekta AB, the global market leader in brachytherapy, on its acquisition of Nucletron.
  • Eurand N.V., a Netherlands-based specialty pharmaceutical company formerly listed on NASDAQ, on the successful tender offer for its shares by Axcan Pharma Holding B.V.
  • Fortissimo Capital and Innovation Industries on their investment in disruptive potato breeder Solynta.
  • Fysicon B.V. and its shareholders on the sale to Canon Medical Systems Cooperation.
  • Gadeta on its strategic cooperation with Kite Pharma.
  • Getinge AB on its acquisition of Applikon Biotechnology
  • Illumina on its acquisition of ThromboDx B.V.
  • Inkef Capital on its series A investment in iOnctura B.V.
  • Johnson & Johnson on its investment in the Dutch biotech company Merus and on its public offer for all ordinary shares of Crucell.
  • Johnson & Johnson's investment in ArgenX and Innovalens.
  • Johnson & Johnson Innovation on its investment in Coöperatieve Gilde Healthcare IV U.A., an alternative investment fund established in the Netherlands, Biogeneration Ventures, GATT, Caelus Pharmaceuticals and other emerging companies.
  • Kester Capital, a UK private equity firm, on its investment in the Dutch leading contract research organisation Factory-CRO.
  • Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT (tm)) products based on CAR and TCR gene therapy platforms for the treatment of cancer, on its acquisition of T-Cell Factory B.V. (TCF (tm)), a privately held Dutch company, which has been renamed Kite Pharma EU.
  • Incyte Corporation in its strategic transaction with and investment in Merus N.V.
  • Mediq Concern B.V., the Netherlands-based supplier of medicines and medical equipment (and its shareholder Advent), on the sale of Mediq Apotheken Nederland to Brocacef Groep N.V., the Dutch-based pharmaceuticals wholesaler and subsidiary of German medical suppliers Phoenix Group and Celesio.
  • Mylan in its EUR 30 billion unsolicited voluntary public offer for Perrigo Company plc, an Ireland based and US and Tel Aviv listed pharmaceuticals company and in relation to the take-over attempt by rival Teva Pharmaceuticals, as well as assisting Mylan in its pending USD 7.5 million bid for Meda.
  • Mylan in its USD 22 billion merger with Pfizer's spin-out Upjohn.
  • Pharmanize in its buy-out by Mentha Capital and existing shareholders.
  • Pharvaris with attracting additional financing to develop and commercialise angioedema drug.
  • Pfizer on the integration of Wyeth, a pharmaceutical company it acquired for $68 billion. A substantial part of Pfizer's and Wyeth's global businesses were and still are structured via the Netherlands, deploying a large number of Dutch holding entities.
  • ProQR Therapeutics in several financing rounds (including Series A) and on its listing on NASDAQ, as well as acting as its key legal adviser on IP, corporate and venture capital transactions.
  • Siemens Healthineers on its strategic collaboration with Screenpoint Medical.
  • Shire Pharmaceuticals/AM-Pharma: advising on a Series D financing round of AM-Pharma.
  • Staten Biotechnology on the collaboration with Novo Nordisk A/S to develop its lead asset STT-5058 for treatment of dyslipidaemia.
  • Tecan Group (SIX Swiss Exchange: TECN), a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics, on its acquisition of 100% of IBL International Holding BV.
  • Thermofisher in its public offer for Patheon N.V.
  • Vemedia Group's acquisition of Vision Healthcare.
  • VarMx on its seed- and series A investment by Innovation Quarter and Biogeneration Ventures.
  • VIB, since end 2012, NautaDutilh is the preferred legal partner of VIB. In recent years, NautaDutilh assisted VIB in three out of four created spin-offs. Amongst those was the creation of the oncology company Oncurious, a JV between VIB and the Euronext-listed biopharmaceutical company ThromboGenics.
  • Vico Therapeutics Holding B.V. on its incorporation and on its series A investment.
  • Wacker on its acquisition of Synco BioPartners.

Capital Markets highlights include assisting:

  • Affimed's underwriters in connection with its IPO on NASDAQ.
  • argenX's underwriters in connection with its announced IPO on NASDAQ.
  • argenx and Merus in their follow-on offerings and Centogene in its Nasdaq IPO, raising a total of up to USD 627.6 million for these companies within 48 hours.
  • Agendi N.V.'s underwriters in connection with its proposed IPO on Euronext Amsterdam (postponed shortly before pricing).
  • Galapagos initial public offering and listing of American depositary shares (ADS) on NASDAQ and private placement in Europe through accelerated book building.
  • InflaRx in its listing on NASDAQ.
  • Kiadis Pharma N.V.'s underwriters in connection with its IPO and the listing of its shaes on Euronext's Amsterdam and Brussels exchanges.
  • Merus shareholders counsel on Merus' IPO.
  • Mylan tender offer for Meda.
  • ProQR Therapeutics in its listing on NASDAQ.
  • Qiagen N.V.'s underwriters in connection with the secondary offering and listing of its shares on the Frankfurt Stock Exchange and NASDAQ.
  • Tigenix's underwriters in connection with its IPO on NASDAQ.
  • uniQure N.V.'s underwriters in connection with its IPO on NASDAQ.

IP and Regulatory Law highlights include assisting:

  • AstraZeneca, review of AstraZeneca's templates with HCPs/HCOs to implement EFPIA/Pharma.be's self-regulatory transparency rules; review of clinical trial agreements and privacy notices for websites and provision of advice in the framework of HCP and patient support programmes (Internet platforms).
  • Boehringer Ingelheim in obtaining a cross-border injunction in the Netherlands against patent infringement by Teva in Portugal.
  • Boehringer Ingelheim in its life cycle management for several medicinal products.
  • Cosmo Technologies Ltd in ground-breaking appeal proceedings against the Dutch MEB.
  • Gilead in relation to the launch of its new product SOVALDI™.
  • Grünenthal, advice on the market entry of an innovative combination product consisting of a device, disposables and a medicinal product.
  • Johnson & Johnson in regulatory and compliance matters.
  • Medtronic in patent litigation concerning medical devices
  • medac GmbH in the Dutch chapter of cross-border patent litigation initiated by Accord Healthcare Ltd. Regarding an auto-inflammatory pharmaceutical drug.
  • Several European commodity importers in an infringement action brought against them by Monsanto in a landmark ruling the European Court of Justice addressed the issue of the scope of DNA patent protection under the Biotech Directive.
  • Pharmacia LLC in patent proceedings initiated by Medis ehf (part of Actavis Group PTC ehf), in which Medis ehf has requested the District Court of The Hague to declare the Dutch part of a European patent of Pharmacia LLC void. The patent concerns a pramipexole product.
  • Sanofi Pasteur MSD in various regulatory and compliance matters.
  • VIB, sole counsel to VIB in drafting new contracts, providing punctual advice and reviewing templates in various areas (NDAs, MTAs, licensing, option, consultancy, research, services, collaboration and development agreements).

Litigation highlights include assisting:

  • Eli Lilly in multiple court proceedings initiated by patients relating to an alleged breach of pharmacovigilance duties and and high profile product liability cases.
  • GlaxoSmithKline in court proceedings relating to alleged adverse events of an antidepressant and high profile product liability cases.
  • Heraeus in its global litigation against Biomet Zimmer.
  • Stichting DES Centrum on the ground-breaking settlement with pharmaceutical companies relating to the adverse events of DES.
  • Astellas in defence against claims relating to alleged adverse events of an incontinence drug.
  • Various pharmaceutical companies in their defence against mass claims initiated by the Hormone Victims Pressure Group.
  • Medtronic in defence against claims relating to alleged defective medical devices.
  • Johnson & Johnson on several complaints and commercial issue.
  • Pfizer in defence against claims relating to alleged adverse events of a contraception drug.

Cookie melding

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.